Company news
Tenaya Therapeutics, Inc. news in 2026
Tenaya Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
November 4, 2026
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
September 14, 2026
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 5, 2026
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 4, 2026
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
June 29, 2026
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
June 3, 2026
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
June 2, 2026
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
May 29, 2026
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
May 15, 2026
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 5, 2026
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
April 27, 2026
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 10, 2026
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
March 8, 2026
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
March 4, 2026
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
March 2, 2026
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
January 9, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 34 slides · September 2026
- Technical Presentation (June 2026)
Technical · 27 slides · Jun 3, 2026
- Jefferies Global Healthcare Conference 2026
Conference · 41 slides · June 2026
- Technical Presentation (May 2026)
Technical · 30 slides · May 15, 2026
- ASGCT 2026
Conference · 13 slides · May 15, 2026